301 related articles for article (PubMed ID: 26240291)
21. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
23. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
[TBL] [Abstract][Full Text] [Related]
24. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
[TBL] [Abstract][Full Text] [Related]
25. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
[TBL] [Abstract][Full Text] [Related]
27. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study.
Zhao R; Ren S; Li C; Guo K; Lu Z; Tian L; He J; Zhang K; Cao Y; Liu S; Li D; Wang Z
Cancer Med; 2023 Feb; 12(4):5158-5171. PubMed ID: 36161527
[TBL] [Abstract][Full Text] [Related]
29. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
[TBL] [Abstract][Full Text] [Related]
30. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma.
Yang Z; LaRiviere MJ; Ko J; Till JE; Christensen T; Yee SS; Black TA; Tien K; Lin A; Shen H; Bhagwat N; Herman D; Adallah A; O'Hara MH; Vollmer CM; Katona BW; Stanger BZ; Issadore D; Carpenter EL
Clin Cancer Res; 2020 Jul; 26(13):3248-3258. PubMed ID: 32299821
[TBL] [Abstract][Full Text] [Related]
31. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
32. Nano-biotinylated liposome-based immunoassay for the ultrasensitive detection of protein biomarker in urine.
Liu P; Fang X; Cao H; Gu M; Kong J; Deng A
Talanta; 2018 Mar; 179():472-477. PubMed ID: 29310262
[TBL] [Abstract][Full Text] [Related]
33. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
34. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach.
Le Large TYS; Meijer LL; Paleckyte R; Boyd LNC; Kok B; Wurdinger T; Schelfhorst T; Piersma SR; Pham TV; van Grieken NCT; Zonderhuis BM; Daams F; van Laarhoven HWM; Bijlsma MF; Jimenez CR; Giovannetti E; Kazemier G
Oncologist; 2020 Apr; 25(4):e634-e643. PubMed ID: 31943574
[TBL] [Abstract][Full Text] [Related]
35. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
36. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
Kandimalla R; Shimura T; Mallik S; Sonohara F; Tsai S; Evans DB; Kim SC; Baba H; Kodera Y; Von Hoff D; Chen X; Goel A
Ann Surg; 2022 Jan; 275(1):e229-e237. PubMed ID: 32398486
[TBL] [Abstract][Full Text] [Related]
37. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
Yip-Schneider MT; Soufi M; Carr RA; Flick KF; Wu H; Colgate CL; Schmidt CM
Am J Surg; 2020 Mar; 219(3):492-495. PubMed ID: 31554598
[TBL] [Abstract][Full Text] [Related]
38. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
39. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
